Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends BioPharma DiveWave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.Clinical DataMetabolic & GLP-1Read full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Maze tumbles despite positive data for kidney disease drugNext: FDA clears Denali drug in ‘clear step’ for rare disease biotechs Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
